Sequel Med Tech and Senseonics have announced a collaboration to integrate Sequel’s twiist Automated Insulin Delivery (AID) System with Senseonics’ Eversense 365 one-year Continuous Glucose Monitoring ...
MANCHESTER, N.H. and GERMANTOWN, Md., Feb. 19, 2026 (GLOBE NEWSWIRE) -- Sequel Med Tech, LLC, a company developing transformative drug delivery technologies, and ...
Senseonics rolls out Eversense 365 integrated with Sequel's twiist AID system, aiming to boost CGM adoption with its year-long wear advantage.
Sequel is committed to offering people with type 1 diabetes greater flexibility and choice in managing their diabetes. Those who use twiist can personalize their diabetes management by choosing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results